Chemours Cuts High End of 2026 Adjusted EBITDA Forecast by $25 Million
Photo: TokenPost
The Chemours Company reset its 2026 profit outlook Nov. 2, trimming $25 million from the high end of its adjusted EBITDA forecast while holding the low end at $775 million. The revised outlook also includes slower expected sales growth and a lower free-cash-flow conversion range. Chemours now projects adjusted EBITDA of $775 million to $800 million, compared with its previous range of $775 million to $825 million. It expects net sales to rise about 2% from 2025, replacing its earlier estimate of 1% to 5% growth.
Source: TokenPost
